Clinical Trial Update: A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 study evaluating CG-105-12 in patients with relapsed/refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CG-105-12

Snippet

Sponsor: The First Affiliated Hospital of Nanchang University | Conditions: Relapsed/Refractory, Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING